↓ Skip to main content

Phase I Oncology Drug Development

Overview of attention for book
Cover of 'Phase I Oncology Drug Development'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 The Development of a Drug: A Pharmaceutical Drug Development Perspective
  3. Altmetric Badge
    Chapter 2 Paradigms in Cancer Drug Development: A Universe with Many Galaxies
  4. Altmetric Badge
    Chapter 3 Preclinical Studies to Enable First in Human Clinical Trials
  5. Altmetric Badge
    Chapter 4 Practicalities of Setting Up a Phase I Clinical Trial Unit Within an Academic Center
  6. Altmetric Badge
    Chapter 5 Novel Trial Designs for Early Phase Clinical Trials
  7. Altmetric Badge
    Chapter 6 Examining Performance of Phase I Designs: 3+3 Versus Bayesian Optimal Interval (BOIN)
  8. Altmetric Badge
    Chapter 7 Considerations for the Attribution and Management of Toxicities in Phase I Clinical Trials
  9. Altmetric Badge
    Chapter 8 Strategies for Incorporating Pharmacokinetic Studies into Oncology Phase I Trials
  10. Altmetric Badge
    Chapter 9 Development of Pharmacodynamic Biomarkers for Phase I Trials
  11. Altmetric Badge
    Chapter 10 Efficacy Considerations in Phase I Trials
  12. Altmetric Badge
    Chapter 11 Considerations for the Development of Novel Chemotherapies and Antibody Drug Conjugates in Phase I Trials
  13. Altmetric Badge
    Chapter 12 Development of Molecularly Targeted Agents in Early Phase Clinical Trials
  14. Altmetric Badge
    Chapter 13 Incorporating Precision Medicine into Phase I Clinical Trials
  15. Altmetric Badge
    Chapter 14 Incorporating Circulating Biomarkers into Clinical Trials
  16. Altmetric Badge
    Chapter 15 Development of Immunotherapeutic Strategies for Early Phase Clinical Trials
  17. Altmetric Badge
    Chapter 16 Radiotherapy Considerations and Strategic Approaches in Phase I Trials
  18. Altmetric Badge
    Chapter 17 The Paradigm of Early Phase Studies in Hematological Malignancies
  19. Altmetric Badge
    Chapter 18 Pharmacokinetic Considerations for Organ Dysfunction Clinical Trials in Early Drug Development
Overall attention for this book and its chapters
Altmetric Badge

Mentioned by

twitter
80 X users

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
7 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase I Oncology Drug Development
Published by
Springer International Publishing, September 2020
DOI 10.1007/978-3-030-47682-3
ISBNs
978-3-03-047681-6, 978-3-03-047682-3
Editors

Yap, Timothy A., Rodon, Jordi, Hong, David S.

X Demographics

X Demographics

The data shown below were collected from the profiles of 80 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 7 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 7 100%

Demographic breakdown

Readers by professional status Count As %
Other 2 29%
Student > Bachelor 2 29%
Professor 1 14%
Professor > Associate Professor 1 14%
Student > Postgraduate 1 14%
Other 0 0%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 3 43%
Pharmacology, Toxicology and Pharmaceutical Science 1 14%
Medicine and Dentistry 1 14%
Engineering 1 14%
Unknown 1 14%